Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Why patients cannot afford to have asthma or gout

Deceased, MD
Meds
April 28, 2014
Share
Tweet
Share

It is noteworthy how certain vital and effective generic drugs for common diseases have become exorbitantly expensive. We are use to new pharmaceutical brands costing a small fortune. But generics, one of which goes back to use in Egyptian times? Really? Allopurinol and asthma inhalers that are cheap but effective medications have become unaffordable to those that need it the most: Simply stated, those that can’t breathe and those that can’t move.

Most people know that drug commercials fill the airwaves with seemingly nonstop advertisements. Most know about the exorbitant costs.

One example, although there are many, is the new hepatitis C drug at $1,000 per pill. Generic asthma inhalers used to be extremely cheap. But with the new environmental laws, they recently were required to change the propellant, which then caused the inhaler to be considered a ‘new” drug with a “new” brand name. This innovative way to gouge the consumer, was a new form of “suffocation” for the asthma patient.

But what is most interesting is how this came about. Big Pharma lobbied for it and made it happen. According to Mother Jones, for around $520,000 cost of lobbying, they succeeded in recreating and repackaging the old generic asthma inhaler for 4-6 times the price. Albuterol, one of the oldest asthma medicines, costs anywhere from $50 to $100 per inhaler in the US, but it was less than $15 a decade ago before it was re-patented.

Why hasn’t hairspray gone up 500 percent?

Do most know that there is a lack of regulation in the pharmaceutical industry and how it affects them?

But it’s the things that you don’t know that can hurt you. For example, Medicare cannot negotiate rates with Big Pharma. Can you imagine selling something where you decide the price and the other party is forced to pay? This is not a free market let’s just say.

What I see clearly is that people that have trouble breathing and moving may no longer afford to move or breathe. To be frank, it’s sort of sadistic, and it’s not subtle. While many argue there is a cost for research and development for branded drugs, these are hard to justify for generics. When one sees a patient suffering from these afflictions and there is a good treatment option, it is kind of cruel to make it cost prohibitive for many, for apparently no good reason, other than to feed the drug manufacturers.

Jonas Salk, MD, is responsible for eradicating polio. His polio vaccine was never patented. He wanted his polio vaccine to save lives throughout the world and to be known throughout history. He was not fueled by greed. As he aptly put it when asked whether there would be a patent for the polio vaccine, he said, “There is no patent. Could you patent the sun?”

“Deceased, MD” is a physician.

Prev

We shouldn’t focus exclusively on patient satisfaction

April 28, 2014 Kevin 6
…
Next

Why I work at the fringe

April 28, 2014 Kevin 6
…

Tagged as: Pulmonology, Rheumatology

Post navigation

< Previous Post
We shouldn’t focus exclusively on patient satisfaction
Next Post >
Why I work at the fringe

ADVERTISEMENT

More by Deceased, MD

  • a desk with keyboard and ipad with the kevinmd logo

    Why so many Americans believe in health care conspiracy theories

    Deceased, MD

More in Meds

  • Why kratom addiction is the next public health crisis

    Muhamad Aly Rifai, MD
  • FDA delays could end vital treatment for rare disease patients

    GJ van Londen, MD
  • Pharmacists are key to expanding Medicaid access to digital therapeutics

    Amanda Matter
  • How medicine repurposing enables value-based pain management and insomnia therapy

    Olumuyiwa Bamgbade, MD
  • Forced voicemail and diagnosis codes are endangering patient access to medications

    Arthur Lazarus, MD, MBA
  • From stigma to science: Rethinking the U.S. drug scheduling system

    Artin Asadipooya
  • Most Popular

  • Past Week

    • Why transgender health care needs urgent reform and inclusive practices

      Angela Rodriguez, MD | Conditions
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • Why pain doctors face unfair scrutiny and harsh penalties in California

      Kayvan Haddadan, MD | Physician
    • mRNA post vaccination syndrome: Is it real?

      Harry Oken, MD | Conditions
    • What street medicine taught me about healing

      Alina Kang | Education
    • The silent cost of choosing personalization over privacy in health care

      Dr. Giriraj Tosh Purohit | Tech
  • Past 6 Months

    • Why transgender health care needs urgent reform and inclusive practices

      Angela Rodriguez, MD | Conditions
    • Why primary care doctors are drowning in debt despite saving lives

      John Wei, MD | Physician
    • Confessions of a lipidologist in recovery: the infection we’ve ignored for 40 years

      Larry Kaskel, MD | Conditions
    • A physician employment agreement term that often tricks physicians

      Dennis Hursh, Esq | Finance
    • Why taxing remittances harms families and global health care

      Dalia Saha, MD | Finance
    • mRNA post vaccination syndrome: Is it real?

      Harry Oken, MD | Conditions
  • Recent Posts

    • Love, birds, and fries: a story of innocence and connection

      Dr. Damane Zehra | Physician
    • Why the future of cancer prevention starts from within

      Raphael E. Cuomo, PhD | Conditions
    • A new approach to South Asian heart health [PODCAST]

      The Podcast by KevinMD | Podcast
    • Private practice employment agreements: What happens if private equity swoops in?

      Dennis Hursh, Esq | Conditions
    • Inside the final hours of a failed lung transplant

      Jonathan Friedman, RN | Conditions
    • Why South Asians in the U.S. face a silent heart disease crisis

      Monzur Morshed, MD and Kaysan Morshed | Conditions

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 44 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Why transgender health care needs urgent reform and inclusive practices

      Angela Rodriguez, MD | Conditions
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • Why pain doctors face unfair scrutiny and harsh penalties in California

      Kayvan Haddadan, MD | Physician
    • mRNA post vaccination syndrome: Is it real?

      Harry Oken, MD | Conditions
    • What street medicine taught me about healing

      Alina Kang | Education
    • The silent cost of choosing personalization over privacy in health care

      Dr. Giriraj Tosh Purohit | Tech
  • Past 6 Months

    • Why transgender health care needs urgent reform and inclusive practices

      Angela Rodriguez, MD | Conditions
    • Why primary care doctors are drowning in debt despite saving lives

      John Wei, MD | Physician
    • Confessions of a lipidologist in recovery: the infection we’ve ignored for 40 years

      Larry Kaskel, MD | Conditions
    • A physician employment agreement term that often tricks physicians

      Dennis Hursh, Esq | Finance
    • Why taxing remittances harms families and global health care

      Dalia Saha, MD | Finance
    • mRNA post vaccination syndrome: Is it real?

      Harry Oken, MD | Conditions
  • Recent Posts

    • Love, birds, and fries: a story of innocence and connection

      Dr. Damane Zehra | Physician
    • Why the future of cancer prevention starts from within

      Raphael E. Cuomo, PhD | Conditions
    • A new approach to South Asian heart health [PODCAST]

      The Podcast by KevinMD | Podcast
    • Private practice employment agreements: What happens if private equity swoops in?

      Dennis Hursh, Esq | Conditions
    • Inside the final hours of a failed lung transplant

      Jonathan Friedman, RN | Conditions
    • Why South Asians in the U.S. face a silent heart disease crisis

      Monzur Morshed, MD and Kaysan Morshed | Conditions

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Why patients cannot afford to have asthma or gout
44 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...